News

About half of the atypical hemolytic uremic syndrome (aHUS) patients had clinically relevant anxiety and more than a quarter met the criteria for post-traumatic stress disorder (PTSD), according to a recent study. “Our cross-sectional survey done a median of [six] years after acute … aHUS demonstrated a substantial burden…

COVID-19 may have triggered a relapse of atypical hemolytic uremic syndrome (aHUS) in a 31-year-old Japanese woman who was previously undiagnosed, according to a recent case study. The relapse occurred while the woman was positive for SARS-CoV-2, the virus that causes COVID-19, and was accompanied by disseminated, or diffuse,…

Soliris (eculizumab) was effective in managing atypical hemolytic uremic syndrome (aHUS), which arose in a man as a side effect of chemotherapy treatment with gemcitabine. “The mainstay management decision [for gemcitabine-related aHUS] is the prompt discontinuation of gemcitabine therapy, and while this is effective in some patients, complement…

A 68-year-old man was diagnosed with atypical hemolytic uremic syndrome (aHUS) that, in an “extremely rare case,” appeared to have been triggered by acute pancreatitis, or inflammation of the pancreas, according to a recent case report.  The patient was admitted to a hospital…

CFH-CFHR1 hybrid genes resulting from an abnormal combination of two genes were identified in a pair of Japanese patients with atypical hemolytic uremic syndrome (aHUS). The genetic variations weren’t observed in healthy people, suggesting aHUS might be related to the hybrid genes being present. “Our study emphasizes that the…

Two identical twins have the same disease-linked mutation in the complement factor B (CFB) gene, but only one developed atypical hemolytic uremic syndrome (aHUS), a recent study reports. Despite only one having aHUS, the identical, or monozygotic, twins had similar levels of complement system activity — a part of…

Soliris(eculizumab) was found to be effective in most patients with atypical hemolytic uremic syndrome (aHUS) when used as a rescue therapy for aHUS recurrence after a kidney transplant, according to a small study. However, many patients also showed persistent kidney failure at…

A substantial number of people with atypical hemolytic uremic syndrome (aHUS) carry rare structural variations in a part of the genome called the CFH-CFHR region and some variants are linked to certain disease manifestations, a recent study reports. “This work highlights the association between aHUS and genomic rearrangements in…

NovelMed has been cleared to begin patient testing of NM8074, an investigational antibody-based therapy for atypical hemolytic uremic syndrome (aHUS) that is not expected to carry a risk of treatment-related infections. The therapy candidate is designed to block the complement cascade — a part of the immune system…

A man with an HIV infection and secondary atypical hemolytic uremic syndrome (aHUS) was successfully treated with Soliris (eculizumab), a case study reported. “This case highlights the unusual presentation and [origin of aHUS], demonstrating the importance of recognizing therapeutic options in primary and secondary settings,” the researchers wrote…